These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 16909001

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer's disease.
    Zurbriggen R, Amacker M, Kammer AR, Westerfeld N, Borghgraef P, Van Leuven F, Van der Auwera I, Wera S.
    J Mol Neurosci; 2005; 27(2):157-66. PubMed ID: 16186626
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
    Imbimbo BP, Del Giudice E, Colavito D, D'Arrigo A, Dalle Carbonare M, Villetti G, Facchinetti F, Volta R, Pietrini V, Baroc MF, Serneels L, De Strooper B, Leon A.
    J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.
    Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith SG, Black RS, Schenk D, Seubert P.
    Ann Neurol; 2005 Sep; 58(3):430-5. PubMed ID: 16130106
    [Abstract] [Full Text] [Related]

  • 28. Magnetic resonance imaging detection and time course of cerebral microhemorrhages during passive immunotherapy in living amyloid precursor protein transgenic mice.
    Luo F, Rustay NR, Seifert T, Roesner B, Hradil V, Hillen H, Ebert U, Severin JM, Cox BF, Llano DA, Day M, Fox GB.
    J Pharmacol Exp Ther; 2010 Dec; 335(3):580-8. PubMed ID: 20823195
    [Abstract] [Full Text] [Related]

  • 29. Reduction of Abeta42 in brains of transgenic APPswe mice by 2-3-chlorophenylaminophenylacetate.
    Cohen MP, Shearman CW.
    Clin Exp Pharmacol Physiol; 2009 Nov; 36(11):1099-103. PubMed ID: 19413589
    [Abstract] [Full Text] [Related]

  • 30. Active full-length DNA Aβ42 immunization in 3xTg-AD mice reduces not only amyloid deposition but also tau pathology.
    Rosenberg RN, Fu M, Lambracht-Washington D.
    Alzheimers Res Ther; 2018 Nov 20; 10(1):115. PubMed ID: 30454039
    [Abstract] [Full Text] [Related]

  • 31. A highly insoluble state of Abeta similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice.
    Philipson O, Hammarström P, Nilsson KP, Portelius E, Olofsson T, Ingelsson M, Hyman BT, Blennow K, Lannfelt L, Kalimo H, Nilsson LN.
    Neurobiol Aging; 2009 Sep 20; 30(9):1393-405. PubMed ID: 18192084
    [Abstract] [Full Text] [Related]

  • 32. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice.
    Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, Hole JT, Forster BM, McDonnell PC, Liu F, Kinley RD, Jordan WH, Hutton ML.
    Neuron; 2012 Dec 06; 76(5):908-20. PubMed ID: 23217740
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology.
    Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, Yednock T.
    Proc Natl Acad Sci U S A; 2003 Feb 18; 100(4):2023-8. PubMed ID: 12566568
    [Abstract] [Full Text] [Related]

  • 36. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition.
    Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE.
    Neurobiol Aging; 2001 Feb 18; 22(5):721-7. PubMed ID: 11705631
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Modulation of Alzheimer's pathology by cerebro-ventricular grafting of hybridoma cells expressing antibodies against Abeta in vivo.
    Gaugler MN, Tracy J, Kuhnle K, Crameri A, Nitsch RM, Mohajeri MH.
    FEBS Lett; 2005 Jan 31; 579(3):753-6. PubMed ID: 15670841
    [Abstract] [Full Text] [Related]

  • 40. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning.
    Schenk D.
    Nat Rev Neurosci; 2002 Oct 31; 3(10):824-8. PubMed ID: 12360327
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.